Conference
Abstract CT122: Randomized assessment of cisplatin dose interval for ototoxicity in the treatment of locally advanced squamous cell carcinoma of the head and neck undergoing curative concurrent chemoradiotherapy (RADIO)
Abstract
Abstract
Background: Recently reported randomized clinical trials (RCTs) have confirmed the importance of concurrent cisplatin in the curative treatment of HPV-related oropharynx cancer treated with definitive radiotherapy (RT) (Mehanna ESMO 2018, Trotti ASTRO 2018). However, the optimal cisplatin dose and schedule in this setting remain unclear. Concurrent high-dose cisplatin (HDC) given every 3 weeks is considered standard …
Authors
Winquist E; Meyers B; Pond G; Hotte S; Black M; Parker C; Nichols A; Palma D; Kim R; Kuruvilla S
Volume
79
Pagination
pp. ct122-ct122
Publisher
American Association for Cancer Research (AACR)
Publication Date
July 1, 2019
DOI
10.1158/1538-7445.am2019-ct122
Conference proceedings
Cancer Research
Issue
13_Supplement
ISSN
0008-5472